Photo from wikipedia
Befovacimab (formerly BAY 1093884) is a fully human monoclonal antibody able to bind to tissue factor pathway inhibitor (TFPI) and developed as a non‐replacement therapy for individuals with haemophilia A/B,… Click to show full abstract
Befovacimab (formerly BAY 1093884) is a fully human monoclonal antibody able to bind to tissue factor pathway inhibitor (TFPI) and developed as a non‐replacement therapy for individuals with haemophilia A/B, with or without inhibitors.
Keywords:
tissue factor;
pathway inhibitor;
factor pathway;
antibody
Journal Title: Haemophilia
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Haemophilia
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!